Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 7, 2015, Pages 2260-2271

  Zumkehr, Joannee ^a   Rodriguez Ortiz, Carlos J ^a   Cheng, David ^b   Kieu, Zanett ^a   Wai, Thin ^a   Hawkins, Charlesice ^a   Kilian, Jason ^a   Lim, Siok Lam ^a   Medeiros, Rodrigo ^b   Kitazawa, Masashi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Astrocyte; GLT 1; Tau

Indexed keywords

AMYLOID BETA PROTEIN; CEFTRIAXONE; GLUTAMATE TRANSPORTER; PROTEIN GLT 1; UNCLASSIFIED DRUG; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; TAU PROTEIN;

AGE; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE MODEL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; TAUOPATHY; UPREGULATION; ANIMAL; ASTROCYTE; BRAIN; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BRAIN; CEFTRIAXONE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; TAU PROTEINS; UP-REGULATION;

EID: 84930082990     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.04.005     Document Type: Article

References (54)

1. Abdul H.M., Sama M.A., Furman J.L., Mathis D.M., Beckett T.L., Weidner A.M., Patel E.S., Baig I., Murphy M.P., LeVine H., Kraner S.D., Norris C.M. Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J. Neurosci. 2009, 29:12957-12969.
2. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
3. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Müller F.-J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13594-13599.
4. Blurton-Jones M., LaFerla F.M. Pathways by which A facilitates tau pathology. Curr Alzheimer Res 2006, 3:437-448.
5. Chen W., Aoki C., Mahadomrongkul V., Gruber C.E., Wang G.J., Blitzblau R., Irwin N., Rosenberg P.A. Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J. Neurosci. 2002, 22:2142-2152.
6. Chen W., Mahadomrongkul V., Berger U.V., Bassan M., DeSilva T., Tanaka K., Irwin N., Aoki C., Rosenberg P.A. The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons. J. Neurosci. 2004, 24:1136-1148.
7. Clarke L.E., Barres B.A. Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 2013, 14:311-321.
8. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 2004, 8:79-84.
9. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65:1-105.
10. de Calignon A., Polydoro M., Suárez-Calvet M., William C., Adamowicz David H., Kopeikina Kathy J., Pitstick R., Sahara N., Ashe Karen H., Carlson George A., Spires-Jones Tara L., Hyman Bradley T. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
11. Dhavan R., Tsai L. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2001, 2:10.
12. Dickson D.W., Crystal H.A., Bevona C., Honer W., Vincent I., Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 1995, 16:285-298.
13. Dickson D.W., Crystal H.A., Mattiace L.A., Masur D.M., Blau A.D., Davies P., Yen S.-H., Aronson M.K. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 1992, 13:179-189.
14. Giannakopoulos P., Herrmann F.R., Bussière T., Bouras C., Kövari E., Perl D.P., Morrison J.H., Gold G., Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-5000.
15. Götz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9:532-544.
16. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
17. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
18. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wölfing H., Chieng B.C., Christie M.J., Napier I.A. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
19. Jacob C., Koutsilieri E., Bartl J., Neuen-Jacob E., Arzberger T., Zander N., Ravid R., Roggendorf W., Riederer P., Grünblatt E. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J. Alzheimers Dis. 2007, 11:97-116.
20. Jimenez-Jimenez F., Molina J., Gomez P., Vargas C., De Bustos F., Benito-Leon J., Tallon-Barranco A., Orti-Pareja M., Gasalla T., Arenas J. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J. Neural Transm. 1998, 105:269-277.
21. Kaiser E., Schoenknecht P., Kassner S., Hildebrandt W., Kinscherf R., Schroeder J. Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease. Neurodegener. Dis. 2010, 7:251-259.
22. Karaman I., Kizilay-Ozfidan G., Karadag C.H., Ulugol A. Lack of effect of ceftriaxone, a GLT-1 transporter activator, on spatial memory in mice. Pharmacol. Biochem. Behav. 2013, 108:61-65.
23. Kayed R., Head E., Sarsoza F., Saing T., Cotman C.W., Necula M., Margol L., Wu J., Breydo L., Thompson J.L., Rasool S., Gurlo T., Butler P., Glabe C.G. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2007, 2:18.
24. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabel C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
25. Kim K., Lee S.G., Kegelman T.P., Su Z.Z., Das S.K., Dash R., Dasgupta S., Barral P.M., Hedvat M., Diaz P. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J. Cell. Physiol. 2011, 226:2484-2493.
26. Kitazawa M., Cheng D., Tsukamoto M.R., Koike M.A., Wes P.D., Vasilevko V., Cribbs D.H., LaFerla F.M. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J. Immunol. 2011, 187:6539-6549.
27. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:8843-8853.
28. LaFerla F.M., Oddo S. Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol. Med. 2005, 11:170-176.
29. Langmann T., Mauerer R., Schmitz G. Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. Clin. Chem. 2006, 52:310-313.
30. Lee S.-G., Su Z.-Z., Emdad L., Gupta P., Sarkar D., Borjabad A., Volsky D.J., Fisher P.B. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J. Biol. Chem. 2008, 283:13116-13123.
31. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
32. Liu L., Drouet V., Wu J.W., Witter M.P., Small S.A., Clelland C., Duff K. Trans-synaptic spread of tau pathology In Vivo. PLoS One 2012, 7:e31302.
33. Masliah E. The role of synaptic proteins in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 924:68-75.
34. Masliah E., Hansen L., Alford M., Deteresa R., Mallory M. Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 1996, 40:759-766.
35. Matos-Ocasio F., Hernández-López A., Thompson K.J. Ceftriaxone, a GLT-1 transporter activator, disrupts hippocampal learning in rats. Pharmacol. Biochem. Behav. 2014, 122:118-121.
36. Mookherjee P., Green P.S., Watson G.S., Marques M.A., Tanaka K., Meeker K.D., Meabon J.S., Li N., Zhu P., Olson V.G. GLT-1 loss accelerates cognitive deficit onset in an Alzheimer's disease animal model. J. Alzheimers Dis. 2011, 26:447-455.
37. Mucke L., Masliah E., Yu G.-Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci 2000, 20:4050-4058.
38. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24:1063-1070.
39. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003, 39:409-421.
40. Pooler A.M., Phillips E.C., Lau D.H.W., Noble W., Hanger D.P. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013, 14:389-394.
41. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Hoberg M.D., Vidensky S., Chung D.S. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
42. Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2006, 27:1372-1384.
43. Scimemi A., Meabon J.S., Woltjer R.L., Sullivan J.M., Diamond J.S., Cook D.G. Amyloid-β1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J. Neurosci. 2013, 33:5312-5318.
44. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
45. Spector R. Ceftriaxone transport through the blood-brain barrier. J. Infect. Dis. 1987, 156:209-211.
46. Sze C.-I., Troncoso J.C., Kawas C., Moution P., Price D.L., Martin L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56:933-944.
47. Talantova M., Sanz-Blasco S., Zhang X., Xia P., Akhtar M.W., Okamoto S.-i., Dziewczapolski G., Nakamura T., Cao G., Pratt A.E., Kang Y.-J., Tu S., Molokanova E., McKercher S.R., Hires S.A., Sason H., Stouffer D.G., Buczynski M.W., Solomon J.P., Michael S., Powers E.T., Kelly J.W., Roberts A., Tong G., Fang-Newmeyer T., Parker J., Holland E.A., Zhang D., Nakanishi N., Chen H.-S.V., Wolosker H., Wang Y., Parsons L.H., Ambasudhan R., Masliah E., Heinemann S.F., Piña-Crespo J.C., Lipton S.A. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2518-E2527.
48. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
49. Tomic J.L., Pensalfini A., Head E., Glabe C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 2009, 35:352-358.
50. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572:477-492.
51. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
52. Woltjer R.L., Duerson K., Fullmer J.M., Mookherjee P., Ryan A.M., Montine T.J., Kaye J.A., Quinn J.F., Silbert L., Erten-Lyons D. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2010, 69:667.
53. Yang Y., Gozen O., Watkins A., Lorenzini I., Lepore A., Gao Y., Vidensky S., Brennan J., Poulsen D., Won Park J., Li Jeon N., Robinson M.B., Rothstein J.D. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 2009, 61:880-894.
54. Zhao L., Ma Q.-L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 2006, 9:234-242.